Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
about
Prevention of vertical transmission of HIV-1 in resource-limited settingsOptimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adultsThe treatment of patients with HIVTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesAntiretroviral treatment regardless of CD4 count: the universal answer to a contextual questionSTART or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus InfectionAntiretroviral therapy for prevention of HIV transmission: implications for EuropeArterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'IvoireCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersOutcomes in a cohort of women who discontinued maternal triple-antiretroviral regimens initially used to prevent mother-to-child transmission during pregnancy and breastfeeding--Kenya, 2003-2009A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsDeclines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, CanadaInitiation of antiretroviral therapy.Challenges in initiating antiretroviral therapy in 2010.Mortality after hospitalization for pneumonia among individuals with HIV, 1995-2008: a Danish cohort studyIncidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil.Effect of early versus deferred antiretroviral therapy for HIV on survival.Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.Late entry into HIV care: estimated impact on AIDS mortality rates in Brazil, 2003-2006.When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment.The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.Who are California's late HIV testers? An analysis of state AIDS surveillance data, 2000-2006.Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in HaitiInitiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.Th17, gut, and HIV: therapeutic implicationsEffects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialImmunologic and virologic events in early HIV infection predict subsequent rate of progression.Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa.Technical performance evaluation of the MyT4 point of care technology for CD4+ T cell enumeration.Brief review: who 2009 guidelines for anti-retroviral theraphy: its implication for primary care physicianEvolution of HIV treatment guidelines in high- and low-income countries: converging recommendationsAntiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades.
P2860
Q22241479-1081B157-6BC3-4B7E-B005-90FD462BFC2FQ24236739-F3E83B5D-DF8A-4BE3-AFE7-FBECE617A058Q24597485-C385F556-B1EC-4CC0-9F5B-02495BBA5267Q24656950-FE22F1DD-8A78-4D3B-8649-C1E5F352BC34Q26741384-B772AB94-24AE-42CA-8D72-90147170147BQ26753830-5CEABE77-9821-460C-92B0-70441C1EBD8AQ27023464-6B6EE6A7-6EAD-4085-B030-4756084B35FFQ27026486-D53B3E43-5CB7-4358-9C3E-291CF739725DQ28475790-F15438E6-3B99-4B3A-A99D-0DCD29CB68BEQ28483820-164E3C9A-D80D-4ED7-BEDE-2829C38FD70EQ28537819-52F80620-5E2A-48F3-A973-8B6337D29DA2Q28543212-C2B3F84A-2C12-4038-9A8F-D109B40A236AQ28610686-24EC6E67-0A0B-4E60-BF77-60E37305E71EQ30209635-C0860409-3EB5-437C-8255-C140CF678B11Q30227046-E366350E-00A3-41D4-B83D-D382390DE812Q33502708-D44A38FE-7D34-458E-AA1A-047403014B73Q33611305-770E5F0B-5BF8-4FF9-8D5F-729137DAC291Q33755753-FCB68E30-898A-4AD6-BDE3-CFDA2E9B4825Q33789114-925E0F45-15E9-4AFC-8C59-0134176BCBF1Q33790033-7EAA9E36-0AEE-4C91-A65F-C6107E932C08Q33808788-D5D6352D-E19C-45E5-A268-0C86FD4AA2FFQ33876261-04EF4731-6DED-4C37-BF93-A64B93CB9479Q33888740-603FD1EF-E480-4326-A0B6-49419ACCF09DQ33889580-05F5D8E3-977D-4B22-8F64-979229F0A563Q33892949-8159D476-BBB0-49FF-86FE-54AEBCD29DAFQ33956969-049C7B1F-603C-4E67-A4A5-3D15B902A228Q34014700-66F111ED-C128-465C-9A4F-8975B6DEDCDEQ34031173-08A80A93-4F3B-4E30-B35A-3B5BEEDD1395Q34040005-59C64050-0A3D-44DD-916B-185129F1CF05Q34050602-A539C921-F0B0-4E62-AB24-F0DEF7BAA92CQ34086963-A1F8F8CD-4C4D-4347-B271-9684795B5C56Q34127870-06556993-E0ED-47B9-902F-5EF3AD95648BQ34170487-39493AE2-B2A7-4965-AE41-DD36A9E7548CQ34206695-17C0056E-4218-4B28-8BD7-1FD6ED890092Q34220828-D2705517-54F9-4998-A27F-5A03E2995B72Q34321843-049B17F9-ABD4-4CB7-8D3F-1DC4F75396AAQ34379806-0D1A8600-44CD-4381-9204-3469E9A0B5B7Q34423991-6A2FA16C-9265-4B53-B2F1-E25C2494C095Q34431819-3A66A16D-FCFC-4021-83F6-B921BC8ECA70Q34440332-38FDDE80-D6BA-4F8D-A8FC-65A8D2F71CA5
P2860
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Major clinical outcomes in ant ...... t baseline in the SMART study.
@ast
Major clinical outcomes in ant ...... t baseline in the SMART study.
@en
Major clinical outcomes in antiretroviral therapy
@nl
type
label
Major clinical outcomes in ant ...... t baseline in the SMART study.
@ast
Major clinical outcomes in ant ...... t baseline in the SMART study.
@en
Major clinical outcomes in antiretroviral therapy
@nl
prefLabel
Major clinical outcomes in ant ...... t baseline in the SMART study.
@ast
Major clinical outcomes in ant ...... t baseline in the SMART study.
@en
Major clinical outcomes in antiretroviral therapy
@nl
P2093
P2860
P50
P356
P1476
Major clinical outcomes in ant ...... t baseline in the SMART study.
@en
P2093
Abdel Babiker
Adrian Palfreeman
Andrew N Phillips
Birgit Grund
Calvin J Cohen
Jacqueline A Neuhaus
Jose M Gatell
Marcelo H Losso
Pierre-Marie Girard
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
P2860
P304
P356
10.1086/586713
P407
P577
2008-04-01T00:00:00Z